Differences in viral and host genetic risk factors for development of human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis between Iranian and Japanese HTLV-1-infected individuals

Autor: Amir H. Sabouri, Mineki Saito, Zahra Sabouri, Zahra Abbaspour, Esmaeil Khayami, Sepideh N. Bajestan, Reza Farid, Mahmoud Mahmoudi, Ali Hasani, Shuji Izumo, Mohsen Forughipour, Mitsuhiro Osame, Mohammad E. Goharjoo, Koichiro Usuku, Kimiyoshi Arimura

Publikováno v: Journal of General Virology. 86:773-781

Human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a neurological disease observed only in 1–2 % of infected individuals. HTLV-1 provirus load, certain HLA alleles and HTLV-1 tax subgroup

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9849fa35ec09289813f1f8d603e86ef7
https://doi.org/10.1099/vir.0.80509-0

Association of AKT1 haplotype with the risk of schizophrenia in Iranian population

Autor: Masayuki Nakamura, Kimiyoshi Arimura, Mohammad R. Sargolzaee, Zahra Sabouri, Hamid Tufani, Mohammad Reza Fayyazi, Mohammad Reza Keikhaee, Sepideh N. Bajestan, Hossein Najmabadi, Nobutaka Eiraku, Mitsuhiro Osame, Esmaeil Khayami, Sima Haghighi, Susan Bany Hashemi, Fatemeh Behdani, Mahboobeh N. Bajestan, Akira Sano, Hiroshi Takashima, Amir H. Sabouri

Publikováno v: American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. (4)

AKT-glycogen synthase kinase 3β (GSK3β) signaling is a target of lithium and has been implicated in the pathogenesis of mood disorders and schizophrenia. AKT1 protein level is decreased in the peripheral lymphocytes and brains of schizophrenic pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edd2403dec0535ac0de2ca533d2fa6da
https://pubmed.ncbi.nlm.nih.gov/16583435

Cutaneous Manifestations in HTLV-I Positive Blood Donors.

Autor: Yazdanpanah MJ; Research centre for Cutaneous Leishmaniasis, Department of Dermatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Maleki M; Research centre for Cutaneous Leishmaniasis, Department of Dermatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Joneidi N; Research centre for Cutaneous Leishmaniasis, Department of Dermatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Khalighi AR; Department of Internal Medicine ,Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Azarpazhooh MR; Department of Neurology, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Khajedaluee M; Department of Social Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Tehranian F; Research Centre of Iranian Blood Transfusion Organization, Khorasan Razavi, Mashhad, Iran., Shahabi M; Research Centre of Iranian Blood Transfusion Organization, Khorasan Razavi, Mashhad, Iran., Esmaeil Khayami M; Research Centre of Iranian Blood Transfusion Organization, Khorasan Razavi, Mashhad, Iran., Livani F; Research centre for Cutaneous Leishmaniasis, Department of Dermatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Publikováno v: Iranian journal of basic medical sciences [Iran J Basic Med Sci] 2013 Mar; Vol. 16 (3), pp. 273-7.